Every S-3 that Cingulate Inc. (CING) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow CING and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CING filings page.
Cingulate Inc. registers up to 4,208,711 shares of common stock for resale by selling stockholders. The registration covers shares issued in a January 27, 2026 private placement, consisting of 2,147,472 issued common shares, 191,824 shares issued upon conversion of Preferred Stock and 1,869,415 shares issuable upon exercise of a warrant.
The company will receive no proceeds from resales by the selling stockholders; however, if the warrant is exercised for cash in full, Cingulate would receive approximately $9.4 million, which it intends to use for regulatory approval and development, manufacturing and commercialization of CTx-1301 and for general corporate purposes.
Cingulate Inc. filed Pre-Effective Amendment No. 1 to its registration statement to add an updated consent of KPMG LLP. The amendment does not modify the prospectus and leaves the registration statement's effective date delayed until the company files a further amendment specifying effectiveness in accordance with Section 8(a) of the Securities Act.
Cingulate Inc. files a prospectus to register up to 3,500,000 shares of common stock that it may elect to issue and sell to Lincoln Park Capital Fund, LLC under a purchase agreement, for resale by Lincoln Park. The prospectus also reflects registration of 6,000,000 shares in total, which includes previously registered and issued shares.
The Purchase Agreement permits Cingulate to sell up to $25.0 million of common stock to Lincoln Park over a 36-month term, subject to a Beneficial Ownership Cap of 4.99% (increaseable to 9.99% with notice). The company will control timing and amount of any sales to Lincoln Park and will receive proceeds only for shares it elects to sell to Lincoln Park under the Purchase Agreement.
Cingulate Inc. registers up to $200,000,000 of securities on a replacement shelf registration statement, enabling future offerings over time. The mixed shelf may include common stock, preferred stock, warrants, debt securities, subscription rights and units, in one or more separate offerings, with terms set by market conditions at each issuance. The filing carries forward $84,854,496 of unsold securities from a 2023 shelf under SEC Rule 415(a)(6). As of January 12, 2026, Cingulate’s public float was $37,286,229.76, limiting sales under this prospectus to no more than one-third of that amount in any 12‑month period while the float remains below $75,000,000, and it has sold $3,588,312.46 pursuant to this rule in the prior 12 months. Cingulate is a biopharmaceutical company developing once‑daily ADHD and anxiety treatments based on its Precision Timed Release platform, and prior audited financials include a going‑concern explanatory paragraph reflecting losses and negative operating cash flows.